Latest News and Press Releases

Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that we have updated the scientific and related content on our corporate website with respect to our...

Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it is nearing the previously-announced expiration date for its rights offering of 5:00 pm Eastern Daylight...

Summit Therapeutics Inc.(‘Summit’ or the ‘Company’) Summit Therapeutics Announces Commencement of Rights Offering Cambridge, MA, April 21, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today...

Cambridge, MA, March 26, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the Company’s Board of Directors has approved a rights offering available to all holders of record of the...

DEINOVE selected for a presentation at the C Diff Foundation annual Conference 2020       ·Yannick Pletan to present the DNV3837 mechanism of action, key features of the antibiotic candidate and the...

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Announces Results of Court Meeting and General Meeting Oxford, UK, and Cambridge, MA, US, August 19, 2020 – Summit Therapeutics plc...

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Announces Intention to Redomicile its Holding Company to the United States Oxford, UK, and Cambridge, MA, US, July 16, 2020 –...

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health Oxford, UK, and Cambridge, MA, US, July 13, 2020...

Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended December 31, 2019, and Operational...

Summit to receive $2.5 million upfront paymentUp to $25 million in development, regulatory, pricing and initial sales milestonesSummit retains commercial rights to ridinilazole in rest of the world ...